Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 9Basaglar
02 10Lantus
03 2Soliqua/iGlarLixi
04 1Soliqua/iGlarLixi
05 9Toujeo
Main Therapeutic Indication : Diabetes
Currency : USD
2014 Revenue in Millions : 11.00%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Diabetes
Currency : USD
2019 Revenue in Millions : 962
2018 Revenue in Millions : 916
Growth (%) : 5
Main Therapeutic Indication : Diabetes
Currency : USD
2019 Revenue in Millions : 3,283
2018 Revenue in Millions : 3,886
Growth (%) : -16
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 195
2019 Revenue in Millions : 148
Growth (%) : 32
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,129
2019 Revenue in Millions : 1,068
Growth (%) : 6
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 3,219
2019 Revenue in Millions : 3,643
Growth (%) : -12
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 215
2020 Revenue in Millions : 175
Growth (%) : 21
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,067
2020 Revenue in Millions : 1,017
Growth (%) : 4
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 2,746
2020 Revenue in Millions : 2,900
Growth (%) : -6
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,225
2021 Revenue in Millions : 1,067
Growth (%) : 15